Videos

Verona Pharma's novel COPD candidate "has the potential to significantly benefit patients," believes CMO Dr Kathleen Rickard

The Company expects to hold an End-of-Phase 2 meeting with the US FDA in the second quarter and anticipates starting Phase 3 later this year.

Living with COPD: I can't breathe

Chris Warburton shares the impact of severe breathlessness on his life."The best you can do is learn how to manage, but not control, your condition. It gradually squeezes the life out of you. Literally."

Chairman David Ebsworth believes in ensifentrine

The first-in-class development candidate has "massive potential to impact lives of COPD and asthma patients."

COPD: We owe our patients better treatments

Millions of patients remain symptomatic despite maximum treatment with available COPD therapies. They urgently need new treatments.

Ensifentrine: Tackling the unmet need

Our first-in-class candidate is effective on top of existing therapies in maximally treated patients with no further treatment options.

COPD: Limited treatment options

Robert Wise, MD, Professor of Medicine at John Hopkins University, explains the urgent need for a COPD therapy with a new mode of action.

Ensifentrine: The story so far

Kathleen Rickard, CMO, explains ensifentrine's clinical progress and plans to enter Phase 3 in 2020.

COPD: A dreadful condition

John Linnell, COPD patient and advocate for the COPD Foundation talks about the difficulty of living with this serious unmet need.

COPD: A cry for help

If a jumbo jet crashed every day, that's the same number of people who die everyday from COPD.

COPD: A beacon of hope

Ensifentrine is a bi-functional molecule that works as a bronchodilator and an anti inflammatory in a single compound.

RPL554: The potential

Verona Pharma's ensifentrine has the potential to address airflow obstruction and persistent inflammation in COPD patients.

Ensifentrine: Unique mechanism of action

Ensifentrine acts as both a bronchodilator and an anti-inflammatory agent in one compound.

Innovative therapies for respiratory care

Learn how Verona Pharma plans to make an impact on serious respiratory diseases.

RPL554: Mechanism of action